Product Images Clopidogrel

Clopidogrel is a medication available in tablet form, with 75mg strength in a package of 30 tablets. It is manufactured by Aurohindo in Nagar, India and repackaged by RemedyRepack Inc. in Indiana, PA. The medication should be stored at a temperature between 15-30°C (59-86°F). Further directions for use are available on the package insert, and the medication should be kept out of the reach of children.*

This is a graph labeled as Figure 1 that shows the effect of administering proton pump inhibitors (PPIs) on the exposure to Clopidogrel Active Metabolite following multiple doses of Clopidogrel Bisulfate 75mg alone. The graph depicts the mean and 90% confidence interval of the effect of co-administered PPIs on the active metabolite AUC. The PPIs mentioned in the graph are Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole. The change relative to Clopidogrel Bisulfate administered alone is also represented on the graph.*

This is a chart displaying the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two treatments, Plagebo with aspirin and Clopidogrel Bisulfate with aspirin, are compared. Standard therapies were also used. The chart shows that Clopidogrel Bisulfate with aspirin has a significantly lower cumulative event rate compared to Plagebo with aspirin (P=0.00009).*

This is a comparative analysis of the effectiveness of placebo and clopidogrel in reducing the risk of death within 28 days of randomization. The percentage of deaths before the first discharge was 8.1% for placebo (1845 deaths) and 7.5% for clopidogrel (1726 deaths), representing a 7% proportional risk reduction with a p-value of 0.03. The data presents a graphical representation of the number of deaths in relation to the days since randomization.*

This text seems to be a table reporting the number of events with percentages for two different treatments or scenarios. The first one is called Placeb and the second one is Clopidogrel. Each treatment has a column with the number of events and their percentage, followed by a proportional risk and a percentage reduction with death, re-infarction, or stroke. The table also includes a timeline from 0 to 28 days since randomization. It is unclear what the events and treatments refer to without further context.*

This appears to be a graph showing the cumulative event rates of fatal or non-fatal vascular events when taking aspirin and clopidogrel bisulfate over time. The x-axis measures the months of follow-up while the y-axis measures the cumulative event rate in percentages.*